Every CEO and CFO evaluating a technology budget asks some version of the same question: which investment actually pays for itself, and how fast? In most industries that question has a straightforward answer built around revenue growth. Hospice is different. Revenue per patient is fixed under the Medicare per-diem benefit, so the return on a technology investment has to show up somewhere else: in nurse hours recovered, in pharmacy costs avoided, or in the ability to add a new location without adding proportional overhead.
That makes ROI conversations in hospice more concrete, not less. A technology investment that doesn't reduce nurse burden, help keep per-patient-day pharmacy spend predictable, or simplify multi-location standardization is competing for budget on hope rather than evidence, and finance committees are right to be skeptical of it.
That reality also changes who needs to be in the room when technology decisions get made. In many hospice organizations, technology purchasing has historically lived with IT or operations alone. When the return depends on nurse time and per-patient-day spend, the CFO and the clinical leadership team need to be part of the evaluation from the start, not brought in after a vendor has already been selected.
Before ranking specific investments, it helps to know where returns realistically appear in a hospice organization's budget.
Not every technology investment creates value in the same way. Three categories map directly to the outcomes hospice leaders are trying to improve.
BetterRX connects ordering, prescribing, approvals, and reporting on one platform through Intelligent Medication Management, which is the piece of The Better Way to Manage Hospice Medications most directly tied to measurable return. Per BetterRX's 2026 Voice of the Customer survey
, clients report saving 5 to 6 hours per nurse per week, time that goes back into patient care rather than administrative coordination.
BetterRX Guardrails™, configured through the Guardrail Manager™, put cost and clinical standards directly into the ordering workflow rather than into a retrospective report, which is why leadership sees spend signals while there's still time to act on them. And because the platform is built to standardize workflows across locations, organizations don't have to rebuild the same operational foundation every time they grow.
This combination is also why BetterRX has earned an “A” Voice of the Customer rating for six consecutive years and reports 94.3% overall client satisfaction across more than 30 evaluation areas, based on feedback from 169 hospice organizations. Those aren't marketing numbers detached from operations. They're a reflection of the same investments this section is describing.
CFOs don't need a complicated model to prioritize technology spend. A short set of questions, applied consistently, does most of the work.
The strongest hospice technology investments improve more than one operational outcome. A platform that gives nurses time back, improves visibility into pharmacy spend, and standardizes workflows across locations can support both predictable PPD and organizational growth without multiplying complexity.
BetterRX's 2025 strategic investment from BVP Forge (Bessemer Venture Partners) supports continued innovation and long-term growth. BetterRX has also been named to the Inc. 5000 list of America's fastest-growing private companies for three consecutive years.